Advances in Targeted Cancer Therapy

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment. TOC:From the contents:Targeting cyclooxygenase-2 for cancer prevention and treatment.- Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate.- Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development.- Tumor models for preclinical development of targeted agents.- Antisense approaches in drug discovery and development.- Obstacles and opportunities in the clinical development of targeted therapeutics.- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.